How to use the Patent Asset Index™ for Patent Portfolio Benchmarking

Posted by Nabu Xavier on Apr 30, 2019 3:40:11 PM

“Being at least as good as the leader is a prerequisite to being competitive.”
— Peter Drucker

 Among the various uses for the Patent Asset Index™, one major area of application is in portfolio Benchmarking. Any company operating in the modern day sets goals for themselves, to guide them towards the success that they strive to achieve. Our unparalleled data quality and multi-pronged analysis tools ensure that decision makers get the right information at the right time to make decisions about the right goals to set.  

Read More

Tags: IP Data Quality, Patent Valuation, Patent Asset Index, IPO Analyses, IP Benchmarking, Patent Quality, Benchmarking


A case study of Palantir: Using advanced patent analytics to aid investment decisions

Posted by Ninja Laufmann on Apr 29, 2019 2:04:15 PM

In a newly released whitepaper PatentSight takes a deep dive into the portfolio of Palantir – one of Silicon Valley’s most secretive companies – to demonstrate how advanced patent analytics can be used to provide critical insights for investment decisions.

Read More

Tags: Technology, Patent Analysis, Patent Valuation, Innovation, Patent Asset Index, IPO Analyses


Insights into Medical Technology Field in light of planned GE Healthcare IPO

Posted by Andreas Lübbering on Mar 15, 2019 12:10:22 PM

Ranked among the top 10 global medical device companies as of revenue, General Electric is now about to file for an IPO to spin out its health-care unit GE Healthcare, as reported by CNBC. With the ongoing jump of Siemens Healthineers shares after their $5 Billion IPO, now GE Healthcare has caught the attention of investors in the medical device market. In this context, PatentSight shed light on the global top 10 medical device companies as of revenue in 2017 from a patent perspective.

Read More

Tags: Mergers and Acquisitions, IP Data Quality, Patent Valuation, Patent Asset Index, IPO Analyses


Israeli Innovation Leader - A patent analysis

Posted by William Mansfield on Mar 12, 2019 9:32:59 AM

Recently, we applied the PatentSight Patent Asset Index methodology to gain a new insight into which of Israel’s research bodies are leading in innovation. The index assesses the strength of an organization’s patent portfolio in terms of quality of patents held measured by TechnologyRelevance™ and Market Coverage ™. So, what did we find?

 

Read More

Tags: Science, Patent Analysis, Innovation, Patent Asset Index


Samsung’s runaway lead in foldable displays by Patent Asset Index™

Posted by William Mansfield on Mar 4, 2019 10:54:00 AM

End of February 2019 Samsung revealed its long rumored smart phone with a foldable display, the first of its kind to have an official release date. A number of players have been rumored to be working on such devices, however Samsung’s combination of in-house smartphone and display technologies may have led to it being first to market.

A closer look at the innovation landscape and the qualitative strength of the patent portfolios in the field of foldable smartphone technology shows the enormous lead Samsung has and the areas in which Apple has to catch up.

Read More

Tags: Technology, Patent Analysis, Innovation, Patent Asset Index


Patent analysis reveals opportunities and concerns around the Bristol-Myers Squibb/Celgene merger

Posted by William Mansfield on Feb 25, 2019 4:46:01 PM

In January of this year, U.S. pharmaceutical manufacturers Bristol-Myers Squibb (BMS) and Celgene Corporation announced they had entered into a definitive merger agreement for BMS to acquire Celgene.

The stated aim of the merger is to create ‘a premier innovative biopharma company’ with a particular focus on building an expanded offering in the cancer and immunotherapy space. If completed, the transaction is expected to cost $74 billion in a cash and stock deal, whereby Celgene shareholders will receive 1.0 BMS share as well as $50 in cash for each share of Celgene.

Our analysis of the two firms’ respective patent portfolios provides insight into how this merger would affect the U.S. pharma market. For this analysis, we employed our Patent Asset IndexTM methodology, which scientifically assesses patent families against Key Performance Indicators of Technology RelevanceTM and Market CoverageTM.

Read More

Tags: Science, Mergers and Acquisitions, Patent Analysis, Patent Asset Index


Tesla to buy Maxwell Technologies: an important technological edge in the battery market for electric cars

Posted by William Mansfield on Feb 7, 2019 9:47:00 AM

With the acquisition of Maxwell Technologies, Tesla expands its patent portfolio and includes technologies that may lead to a major advantage in the future technology of efficient batteries for electric cars. The company is a specialist in the field of energy storage. For Tesla this can mean a leap forward in the highly competitive field of battery technology for electric cars. A closer look at this acquisition scenario shows us in which technology areas Maxwell can significantly complement Tesla's patent portfolio.

Read More

Tags: Technology, Mergers and Acquisitions, Patent Analysis, Innovation, Patent Asset Index


Application fields and active protection - A closer look at the top 20 Universities and Research centers

Posted by William Mansfield on Jan 11, 2019 3:53:59 PM

For a study commissioned by IAM, PatentSight has taken a closer look at the patenting activity of leading universities and research centers based on the Patent Asset IndexTM.

Read More

Tags: Technology, Science, Innovation, Patent Asset Index


The Top 20 Most Innovative Chinese Universities

Posted by LexisNexis PatentSight team on Nov 12, 2018 1:15:01 PM

 跳转到简体中文 (jump to Simplified Chinese):

中国高校创新力前20强

 

Today, LexisNexis published a ranking of China’s top 20 most innovative universities based on their patent assets. Analysts at LexisNexis have identified these top universities as sorted by the Patent Asset Index™.

 

Read More

Tags: Technology, Science, Patent Valuation, Innovation, Patent Asset Index


Roche up, Pfizer out - The Patent Asset Index™ for Alzheimer’s and Parkinson’s patents

Posted by Benjamin Hann on Oct 16, 2018 8:33:56 AM

 

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

Read More

Tags: Patent Analysis, Patent Valuation, Patent Asset Index